Invitae said this week that it completed its acquisition of Singular Bio on June 19.
The cancer diagnostics developer said it was undertaking the reverse stock split in order to meet the Nasdaq's $1 minimum bid price requirement.
The university will use the technology to screen blood samples for certain clinically actionable mutations in non-small cell lung cancer patients.
Precipio said that its ICE COLD-PCR reagents will be sold with PerkinElmer's DNA/RNA extraction and isolation products.
The revenue growth was fueled by continued volume increases in Precipio's pathology services unit, which benefited from a recently expanded sales team.
The company had been warned in March that it failed to meet a listing requirement calling for a minimum $1 per share closing price of its common stock.
The company, which merged with Transgenomic in 2016, attributed the revenue increase to strong demand for its pathology services.
The suit alleged that Precipio failed to meet the obligations of a securities agreement signed by Transgenomic, which it acquired last year.
An initial analysis suggests the novel coronavirus from Wuhan that is sickening people might come from snakes, a team of virologists writes at the Conversation.
DNA testing confirms captured Chicago coyote same as the one that bit a boy near a nature museum, the Chicago Tribune reports.
An analysis of Tibetan ice cores uncovers more than two dozen previously unknown virus groups, LiveScience reports.
In Nature this week: genomic analysis of four children buried in Cameroon approximately 3,000 and 8,000 years ago, and more.